

# **GAMMA KNIFE RADIOSURGERY FOR FUNCTIONING PITUITARY ADENOMAS**

*A Thesis submitted in partial fulfillment of the conditions for the  
award of a Medical Doctorate (MD) Degree in Neurosurgery*

**By**

**ESENE IGNATIUS NGENE**

M.B.B Ch., M.Sc Neurosurgery  
Faculty of Medicine, Ain Shams University

**Under Supervision of**

**Prof. Dr. HOSSAM MOHAMED EL- HUSSENI**

Professor of Neurosurgery,  
Faculty of Medicine, Ain Shams University

**Prof. Dr. Wael Abdel Halim Reda**

Professor of Neurosurgery,  
Faculty of Medicine, Ain Shams University

**Prof. Dr. Hamdy Ibrahim Khalil**

Professor of Neurosurgery,  
Faculty of Medicine, Ain Shams University

**Prof. Tarek Hamdy ElSerry**

Assistant Professor of Neurosurgery,  
Faculty of Medicine, Ain Shams University

**FACULTY OF MEDICINE  
AIN SHAMS UNIVERSITY**

**2016**

# ACKNOWLEDGEMENT

I will like to express my sincere appreciation to the following who supported my training in Neurosurgery and/or assisted me in one way or the other to carry out this thesis:

✚ ALMIGHTY GOD

✚ Thesis Supervisors :

- Prof. Dr. HOSSAM MOHAMED EL- HUSSENI
- Prof. Dr. WAEL ABDEL HALIM REDA
- Prof. Dr. HAMDY IBRAHIM KHALIL
- Prof. TAREK HAMDY ELSERRY

✚ Prof. Dr Emad Ghanem and the Staff of the Department of Neurosurgery, Ain Shams University.

✚ Dr Amr Refaat and the Staff of Cairo Gamma Knife Center,

✚ H.E Dr Mohamadou Labarang-Ambassador of Cameroon to Egypt and Staff of the Cameroonian Embassy,

✚ Prof. Madjid Samii-WFNS Ambassador For Africa and World Federation of Neurosurgical Societies (WFNS) and

✚ My Family, Friends and Colleagues.

## Contents

|                                                           |    |
|-----------------------------------------------------------|----|
| ABBERRIATIONS .....                                       | 5  |
| LIST OF TABLES .....                                      | 6  |
| LIST OF FIGURES .....                                     | 7  |
| 1. INTRODUCTION .....                                     | 9  |
| 2. OBJECTIVES .....                                       | 11 |
| 3. REVIEW OF LITERATURE .....                             | 12 |
| 3.1 HISTORICAL PERSPECTIVE .....                          | 12 |
| 3.2 EMBRYOLOGY OF THE PITUITARY .....                     | 13 |
| 3.3 ANATOMY OF THE PITUITARY GLAND AND SELLA .....        | 14 |
| 3.4 RADIOLOGICAL ANATOMY OF THE PITUITARY AND SELLA ..... | 22 |
| 3.5 PHYSIOLOGY OF THE PITUITARY GLAND .....               | 24 |
| 3.6 PATHOLOGY OF PITUITARY ADENOMAS .....                 | 31 |
| 3.7 CLINICAL PRESENTATION .....                           | 39 |
| 3.8 DIAGNOSTIC APPROACH FOR PITUITARY ADENOMAS .....      | 50 |
| 3.9 TREATMENT OF PITUITARY ADENOMAS .....                 | 64 |
| 4. METHODOLOGY .....                                      | 86 |
| 4.1 STUDY DESIGN .....                                    | 86 |
| 4.2 TIME FRAME .....                                      | 86 |
| 4.3 STUDY SITE (SETTING) .....                            | 86 |
| 4.4 STUDY POPULATION (PARTICIPANTS) .....                 | 86 |
| Sampling & Recruitment .....                              | 86 |
| Sample Size Justification .....                           | 87 |
| Inclusion Criteria .....                                  | 87 |
| Exclusion Criteria .....                                  | 88 |
| 4.5 PROCEDURE (PATIENT MANAGEMENT) .....                  | 88 |

|                                                |                                     |
|------------------------------------------------|-------------------------------------|
| 4.6 FOLLOW UP .....                            | 99                                  |
| 4.7 STATISTICAL METHODOLOGY .....              | 101                                 |
| 4.8 ETHICAL CLEARANCE.....                     | 102                                 |
| 4.9 CONFLICT OF INTEREST .....                 | 102                                 |
| 5. RESULTS .....                               | 103                                 |
| 5.1 BASELINE CHARACTERISTICS OF PATIENTS ..... | 103                                 |
| 5.2 TREATMENT OF THE PATIENTS .....            | 110                                 |
| 5.3 INDICATIONS FOR GK RADIOSURGERY .....      | 113                                 |
| 5.4 OUTCOME AFTER GK RADIOSURGERY .....        | 114                                 |
| 6. ILLUSTRATED CASES .....                     | 130                                 |
| 7. DISCUSSION .....                            | 138                                 |
| STUDY JUSTIFICATION .....                      | 138                                 |
| GOALS OF STUDY.....                            | 138                                 |
| STUDY METHODOLOGY .....                        | 139                                 |
| OUTCOME ASSESSMENT AFTER GK RADIOSURGERY. .... | 139                                 |
| 8. CONCLUSION .....                            | 153                                 |
| 9. SUMMARY (ENGLISH) .....                     | 154                                 |
| 10. SUMMARY (ARABIC) .....                     | <b>Error! Bookmark not defined.</b> |
| 11. LIST OF REFERENCES.....                    | 156                                 |

## ABBREVIATIONS

| Abbreviation    | Full Meaning                                  |
|-----------------|-----------------------------------------------|
| <b>3D</b>       | Three Dimensional                             |
| <b>ACTH</b>     | Adrenocorticotropin Hormone                   |
| <b>ACTH-oma</b> | Adrenocorticotropin Hormone Secreting Adenoma |
| <b>CRH</b>      | Corticotropin Releasing Hormone               |
| <b>CS</b>       | Cavernous Sinus                               |
| <b>CSF</b>      | Cerebro Spinal Fluid                          |
| <b>CT</b>       | Computerized Tomography                       |
| <b>D2</b>       | Dopamine 2                                    |
| <b>DA</b>       | Dopamine Agonist                              |
| <b>ENT</b>      | Ear Nose And Throat                           |
| <b>FSH</b>      | Follicle Stimulating Hormone                  |
| <b>FPA</b>      | Functioning Pituitary Adenoma                 |
| <b>GH-oma</b>   | Groth Hormone Secreting Adenoma               |
| <b>GH</b>       | Growth Hormone                                |
| <b>GnRH</b>     | Gonadotropin Releasing Hormone                |
| <b>GHRH</b>     | Growth Hormone Releasing Hormone              |
| <b>HE</b>       | Hematoxylin–Eosin                             |
| <b>ICA</b>      | Internal Carotid Artery                       |
| <b>IGF-1</b>    | Insulin Growth Factor 1                       |
| <b>IPSS</b>     | Inferior Petrosal Sinus Sampling              |
| <b>IRMA</b>     | Immunoradiometric Assay                       |
| <b>LH</b>       | Luteinizing Hormone                           |
| <b>MEN</b>      | Multiple Endocrine Neoplasia                  |
| <b>MRI</b>      | Magnetic Resonance Imaging                    |
| <b>NFA</b>      | Clinically Nonfunctioning Adenoma             |
| <b>OGTT</b>     | Oral Glucose Tolerance Test                   |
| <b>PRL</b>      | Prolactin                                     |
| <b>PRL-oma</b>  | Prolactin Secreting Adenoma                   |
| <b>T4</b>       | Free Thyroxin                                 |
| <b>TRH</b>      | Thyrotropin Releasing Hormone                 |
| <b>TSH</b>      | Thyroid Stimulating Hormone                   |
| <b>UFC</b>      | Urine Free Cortisol                           |
| <b>VEP</b>      | Visual Evoked Potentials                      |
| <b>WHO</b>      | World Health Organization                     |

## LIST OF TABLES

|                                                                                                   |     |
|---------------------------------------------------------------------------------------------------|-----|
| Table 1: Neuroanatomical classification of pituitary adenomas.....                                | 34  |
| Table 2: Classification of Pituitary Tumors (WHO).....                                            | 36  |
| Table 3:Differential diagnosis of sellar masses. ....                                             | 49  |
| Table 4: Baseline Demographic Characteristics of the patients .....                               | 103 |
| Table 5: Baseline Clinical Characteristics of the patients.....                                   | 104 |
| Table 6: Baseline Clinical Features of prolactinomas .....                                        | 105 |
| Table 7: Baseline Visual Manifestations of the patients.....                                      | 106 |
| Table 8: Type of Visual Affection .....                                                           | 107 |
| Table 9: History of previous surgery .....                                                        | 107 |
| Table 10: Time Interval between last surgery and Gamma Knife Treatment. ....                      | 108 |
| Table 11: Tumor operative status before Gamma Knife Treatment. ....                               | 108 |
| Table 12: Tumor Location and Associated findings.....                                             | 109 |
| Table 13: Treatment parameters .....                                                              | 111 |
| Table 14: Tumor Status of the patient before Gamma Knife Radiosurgery .....                       | 113 |
| Table 15: Medication status for prolactinomas before GKS .....                                    | 114 |
| Table 16: Tumor Volume and Biochemical control .....                                              | 115 |
| Table 17 : Hormone Normalization Rates with Time .....                                            | 116 |
| Table 18:Pre- and Post-Radiosurgery Hormonal Levels.....                                          | 118 |
| Table 19: Factors affecting hormonal normalization .....                                          | 119 |
| Table 20: Factors affecting tumor shrinkage .....                                                 | 123 |
| Table 21: Association between prescription dose and tumor shrinkage stratified by tumor type..... | 124 |
| Table 22: Visual outcome after GK Radiosurgery (Per Eye).....                                     | 126 |
| Table 23: Factors affecting visual outcome (Normalization) .....                                  | 127 |

## LIST OF FIGURES

|                                                                                           |    |
|-------------------------------------------------------------------------------------------|----|
| Figure 1: Embryogenesis of the pituitary gland .....                                      | 13 |
| Figure 2: The pituitary gland and its relationships .....                                 | 14 |
| Figure 3: Superior view of pituitary gland .....                                          | 16 |
| Figure 4: Optic Chiasm .....                                                              | 17 |
| Figure 5: Cavernous Sinus.....                                                            | 18 |
| Figure 6: Sagittal sections of the sellar region.....                                     | 19 |
| Figure 7: Types of sphenoid sinus .....                                                   | 20 |
| Figure 8: Sphenoid Sinus .....                                                            | 21 |
| Figure 9: Pituitary cell types distribution within the adenohypophysis .....              | 24 |
| Figure 10: Pituitary Neuroendocrinology.....                                              | 25 |
| Figure 11:Hypothalamo-Hypophysial Portal Circulation .....                                | 28 |
| Figure 12: Hypothalamo-Hypophysial Tract.....                                             | 29 |
| Figure 13: Pathological diagnosis in pituitary adenomas.....                              | 32 |
| Figure 14: Normal MRI Sella .....                                                         | 58 |
| Figure 15:Dynamic and standard coronal image of a microadenoma .....                      | 59 |
| Figure 16: MRI evaluation of a pituitary macroadenoma .....                               | 60 |
| Figure 17: Hardy's classification of pituitary adenoma .....                              | 61 |
| Figure 18: The KNOSP Classification .....                                                 | 62 |
| Figure 19: Management Choices for Pituitary Adenomas .....                                | 74 |
| Figure 20: The 3-D Cartesian Axes of a Stereotactic System .....                          | 77 |
| Figure 21: Effects of Ionizing radiation over time.....                                   | 81 |
| Figure 22: The Leksell Gamma Knife PERFEXION .....                                        | 83 |
| Figure 23: Leksell GK PERFEXION radiation unit and collimator system .....                | 83 |
| Figure 24: Sample size justification.....                                                 | 87 |
| Figure 25: Gamma Knife coordinate frame. (Image Courtesy of Elekta, Inc.).....            | 90 |
| Figure 26: Leksell frame G tray (frame, posts, screws, and screw drivers) .....           | 91 |
| Figure 27: MRI box in place.....                                                          | 91 |
| Figure 28: Placement of plastic cap .....                                                 | 92 |
| Figure 29: Fixation of the plastic 'bubble' to the frame and taking of measurements ..... | 94 |
| Figure 30: Patient in the MRI Unit .....                                                  | 95 |
| Figure 31: Typical planning with Gamma Knife Perfexion .....                              | 97 |
| Figure 32: Positioning of patient for Treatment .....                                     | 98 |

|                                                                                                      |     |
|------------------------------------------------------------------------------------------------------|-----|
| Figure 33: Age Distribution by Pituitary Adenoma Sub-Type.....                                       | 103 |
| Figure 34: Kaplan Meier Curve for Hormone Normalization.....                                         | 117 |
| Figure 35: Kaplan Meier survival for tumor shrinkage.....                                            | 122 |
| Figure 36: Case N° 1 : MRI Sella (Axial Cuts). A (Pre-) & B (Post)- Radiosurgery.....                | 130 |
| Figure 37: Case N° 1: Visual Field (Pre- & Post- Radiosurgery).....                                  | 131 |
| Figure 38: Case N° 2: MRI Brain (Coronal (A) & Axial Cuts(B)): Pre-GK Radiosurgery..                 | 132 |
| Figure 39: Case N° 2: MRI Brain (Coronal Cuts): Post-GK Radiosurgery .....                           | 132 |
| Figure 40: Case N° 2: Visual Field (Pre- & Post- Radiosurgery).....                                  | 133 |
| Figure 41: Case N° 3: MRI sella (Coronal Cuts): A (Pre)- B (Post) Surgery & C (Post-Dostinex) .....  | 134 |
| Figure 42: Case N° 3 : MRI sella (Coronal Cuts): A (Post MicroSurgery) & B (Post-Radiosurgery) ..... | 134 |
| Figure 43: Case N° 3: Visual Field (Pre- & Post- Radiosurgery).....                                  | 135 |
| Figure 44: Case N° 4: Pre- (A) & Post-(B) Radiosurgery MRI .....                                     | 136 |
| Figure 45: Case N° 4: Visual Field (Pre- & Post- Radiosurgery).....                                  | 137 |



# 1. INTRODUCTION

## RATIONALE AND JUSTIFICATION OF STUDY

Pituitary adenomas are amongst the most common intracranial lesions, constituting 10-20% of primary brain tumors. They have a reported annual incidence in the general population close to 20%<sup>1</sup>. Pituitary adenomas are generally classified as either “functioning” or “non-functioning,” with the former (secreting adenomas) representing about 70% of all pituitary tumors<sup>2, 3</sup>. Classically, pituitary adenomas present with a **clinical** triad related to hypersecretion/hypopituitarism, mass effect or as incidentalomas; occasionally as pituitary apoplexy, or rarely as cerebrospinal fluid rhinorrhoea<sup>4</sup>.

A suspected case of pituitary adenoma will require a coordinated two step **diagnostic approach** to establish the endocrine and the anatomical diagnosis via an initial clinical assessment, complemented by a spectrum of endocrinologic and neuroimaging tests. Additionally a neuroophthalmologic assessment is routinely required<sup>4</sup>.

The management of pituitary adenomas requires a multidisciplinary approach. The current therapeutic armamentarium includes medical, surgical and radiotherapeutic methods with the latter being rapidly replaced by radiosurgery. Pituitary tumors are well-suited for radiosurgery, since radiation can be focused on a well circumscribed region, while adjacent neural structures in the suprasellar and parasellar regions are spared<sup>2, 3, 5-9</sup>.

Stereotactic radiosurgery uses sophisticated 3-D computerized imaging to precisely target an ionizing ray and deliver a high concentrated dose of radiation to the lesion. Stereotactic radiosurgery differs and is advantageous over conventional surgery because there is no incision involved and general anesthesia is not required for adults, and short treatment duration amongst others<sup>5, 6</sup>.

The expected dominance of the time-honored microscopic pituitary surgery technique as the “gold standard” for pituitary surgery seems to be fading out while the endoscopic techniques are on a rise. Microsurgical resection alone provides a long-term tumor control rate of only 50% to 80% and a long-term remission rate of endocrinologic normalization after surgical resection that often falls short of expectations. Reoperation for residual or recurrent tumors is associated with the more difficult complete resection and the endoscopic method alone is insufficient to solve all problems associated with these cases<sup>7</sup>. There is thus need for a complementary technique.

Most studies involving SRS for nonfunctioning pituitary adenomas (NFAs) have shown excellent tumor volume control, with a mean tumor control rate of 93% (range: 68%-100%). However in FPAs, this type of treatment remains challenging. Literature on SRS for FPAs is variable with reported rates of 35-83% for Cushing’s disease, 42-60% for acromegaly, and 26-43% for prolactinomas<sup>5</sup>.

The main goals of SRS for FPAs are to normalize excessive hormonal production and control tumor growth<sup>7</sup>. The rationale of our study is to define accurately the effectiveness, safety, complications, and role of the Gamma Knife Radiosurgery for the treatment of secretory pituitary adenomas in our population.

## 2. OBJECTIVES

### GENERAL OBJECTIVE

To assess the effectiveness, safety, complications, and role of the gamma knife for the treatment of functioning pituitary adenomas (FPAs).

### SPECIFIC OBJECTIVES

- ✚ To evaluate the effectiveness of Gamma Knife Radiosurgery in terms of biochemical remission and tumor control and explore factors affecting them.
- ✚ To assess the morbidity association with Gamma Knife Radiosurgery for functioning pituitary adenomas

# 3. REVIEW OF LITERATURE

## 3.1 HISTORICAL PERSPECTIVE

The anatomy of the pituitary gland has been known since the Greek and Roman antiquity through the works of Hippocrates and Galen. The latter propagated that the pituitary was the route for the « disposal of waste products of the brain », a concept taught to medical students for millennia. The work of Vespasian during the Renaissance raised questions about the concepts introduced by Galen but the relationship between « disease » and « pituitary tumors » only actually began with the introduction of anatomical and clinical methods in the 17th century<sup>10</sup>.

Andreas Vesalius (1543) believed the pituitary produced mucus, secreted by the brain into the nasal cavity hence the name “glandula pituitaria” (pituita=mucus). Jean Louis Petit (1674-1750) showed that the development of a pituitary tumor can cause blindness.

Pierre Marie (1853-1940), in 1886, demonstrated the relationship between symptoms of acromegaly and pituitary tumor.

The link between Hypopituitarism and malfunction of the pituitary gland was established in 1901 by A Froelich (1871-1953) and H Cushing in his book "The Pituitary Body and Its Disorders" describing the different clinical pictures of hypo or hyper secretion<sup>10</sup>.

The pituitary gland (master gland) controls the activities of the other endocrine glands. Knowledge of its anatomy and physiology is important for proper management of pituitary tumors.

## 3.2 EMBRYOLOGY OF THE PITUITARY

The sella develops as a depression in the body of the sphenoid, is lined with dura and houses the pituitary gland. The pituitary gland develops from two different structures<sup>11</sup>:

**An Upward Ectodermal Growth** [Oral ectoderm of the primitive buccal cavity (stomatodeum)] from the roof of the pharynx that passes cranially as the Rathke's pouch forming the anterior portion of the pituitary (adenohypophysis).

**A Downward Neural Growth** (projection of the hypothalamus) from the floor of the third ventricle (base of the diencephalon) forming the posterior lobe (neurohypophysis) and pituitary stalk.




Figure 1: Embryogenesis of the pituitary gland

These two meet in the sella turcica and the stalk of the Rathke's pouch degenerates (loses connection with the pharynx) while the stalk of the neural growth persists and forms the pituitary stalk (infundibulum).

The Rathke's pouch develops into three parts : Pars Distalis (pars glandularis), Pars Tuberalis and Pars Intermedia .

The downward neural growth develops into the pars nervosa forming the posterior lobe to which the intermediate lobe becomes closely adherent and is separated from the anterior lobe by a remnant of *Rathke's pouch* called the *Rathke's Cleft*.

This composite gland is distinct and separate from the primitive stomatodeum by the seventh week of gestation and further develops under the influence of the hypothalamus through a series of permissive and specific trans-acting proteins<sup>11</sup>.

### 3.3 ANATOMY OF THE PITUITARY GLAND AND SELLA

The pituitary gland is a small reddish grey gland **0.5-1 g** in weight. It is situated in the *sella turcica* (*hypophysial fossa*) and is attached to the floor of the third ventricle of the brain by a stalk (*infundibulum*)<sup>12</sup>. On a coronal section through the brain the pituitary gland reference structure (Figure 2).




Figure 2: The pituitary gland and its relationships

(Courtesy of Roton <sup>12</sup>)

The pituitary measures **7 mm x 9mm x 11mm** in the height, antero-posterior and transverse diameter respectively.

It has three lobes: A large glandular anterior lobe (the adenohypophysis or anterior pituitary gland), a small intermediate lobe (rudimentary in humans) and a large neuronal posterior lobe (the neurohypophysis or posterior pituitary gland)<sup>12</sup>.

The **Adenohypophysis** has three regions<sup>12</sup>:

The *pars tuberalis* which is applied to the median eminence and upper infundibular stem (rostral region of the neurohypophysis) and is an extension of the glandular hypophysis that lies above the sella turcica.

The *pars intermedia* is applied to the lower portion of the lower infundibular stem and the infundibular process (caudal regions of the neurohypophysis)

The *pars distalis*, the main bulk of the adenohypophysis is composed of epithelial cells arranged in a glandular pattern, folliculostellate cells arranged in a syncytium and fenestrated capillaries and has no axonal terminals.

The **Neurohypophysis** based on regional morphologic specialization is subdivided into three regions<sup>12</sup>:

The *Median Eminence* which together with the two lateral eminences make up the *tuber cinereum* visible on the inferior surface of the brain, caudal to the *optic chiasm* and rostral to the paired *mammillary bodies*

The *Infundibular Stem* is the neural portion of the pituitary stalk.

The *Neural Lobe* is the pars nervosa.

## **Dural, Neural & Vascular Relations Of The Pituitary**<sup>12, 13</sup>

The pituitary by virtue of its position is related to many vital structures.

*Inferiorly*: It sits in the sella turcica separated from the bone by dura.

*Superiorly*: Optic chiasm and nerves

*Laterally*: The cavernous sinus with its content.

*Posteriorly*: basilar artery and brain stem